I would love to see SNY partner up with CUR as CUR is making great progress with ALS and SNY has the only current therapy for ALS. CUR is focused on regenerative medicine and SNY is still into mitigation of symptoms. Hopefully SNY will take a leadership role developing therapies of the future. I own both SNY and CUR. If SNY does not partner it is only a matter of time that a competitor steps in as CUR will need a partner to market and mass produce their product line. The product line also addresses stroke and depression disorders so the stock offers a multivalent investment opportunity to the interested suitor. China is particularly interested in the stroke application as their health costs for their aged population will soon impede their ability to buy US Bonds and that would indirectly impact their sales. this is why they are looking to focus on cures (no pun intended here) rather than costly mitigation of symptoms.